Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
08:01am, Wednesday, 22'nd Nov 2023
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p
ABBV vs. LLY: Which Stock Should Value Investors Buy Now?
12:47pm, Tuesday, 21'st Nov 2023
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both AbbVie (ABBV) and Eli Lilly (LLY). But which of these two stocks offers value investors a better bang for th
GLOBALT Investments' Keith Buchanan on his top stock picks: WMT, LLY, JPM
09:09am, Tuesday, 21'st Nov 2023
Keith Buchanan, GLOBALT Investments senior portfolio manager, joins 'Squawk Box' to discuss his top stock picks, including Walmart, Eli Lilly, and JPMorgan Chase.
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
05:30am, Tuesday, 21'st Nov 2023
Pfizer and AbbVie face headwinds right now, but their long-term outlooks remain bright. Both stocks trade for a bargain today.
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
12:47pm, Monday, 20'th Nov 2023
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Medicare's exclusion of weight-loss drug coverage under fire
12:26pm, Monday, 20'th Nov 2023
Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:31am, Monday, 20'th Nov 2023
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Billionaires Bullish on Big Tech: ETFs in Focus
09:46am, Monday, 20'th Nov 2023
The latest 13-F filings of billionaires indicate that most are still bullish on big techs.
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
06:05am, Sunday, 19'th Nov 2023
Eli Lilly's approval for its obesity drug Zepbound is a huge step forward in its attempt to take market share from its top rival Novo Nordisk. The combination of Mounjaro and Zepbound could reach near
Weight loss drugs Wegovy and Zepbound to debut in pill form
10:51am, Friday, 17'th Nov 2023
Popular weight loss drugs Wegovy and Zepbound will soon be available in pill form. Pharmaceutical giants Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) are actively promoting pill versions of
Eli Lilly plans $2.5B site in Germany to expand injectable manufacturing capacity
09:21am, Friday, 17'th Nov 2023
Eli Lilly and Co (NYSE:LLY) has announced plans for a new $2.5 billion high-tech manufacturing site in Germany to expand its global parenteral (injectable) product and device manufacturing network. Th
13F Rundown: Tepper, Buffett, Druckenmiller
09:01am, Friday, 17'th Nov 2023
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Eli Lilly to build $2.5 billion plant in Germany to support rising demand for obesity, diabetes drugs
08:12am, Friday, 17'th Nov 2023
Shares of Eli Lilly & Co. LLY, +0.04% rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany. The new facility i
Retail investors crowd into Eli Lilly after weight-loss drug approval
08:03am, Friday, 17'th Nov 2023
Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weigh
Weight loss drugs and stocks: Breaking down the GLP1 market for investors
11:42am, Thursday, 16'th Nov 2023
Weight loss drugs are at the forefront of demand in the pharmaceutical sector as major drug manufacturers Novo Nordisk (NVO) and Lilly (LLY) undergoing clinical trials for new GLP-1 drugs. And, one an
